Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb) in Patients With ErbB2-Positive Stage I-III Breast Cancer.

Next Previous
Search
Trial Profile

Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb) in Patients With ErbB2-Positive Stage I-III Breast Cancer.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use

Most Recent Events

  • 14 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
  • 23 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top